Sandra Fernandez-Morana

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fraction.

Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fraction.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 12, 2025

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Journal: European journal of clinical investigation

Published: August 06, 2024

Effects of Sodium Nitroprusside on Lipopolysaccharide-Induced Inflammation and Disruption of Blood-Brain Barrier.

Effects of Sodium Nitroprusside on Lipopolysaccharide-Induced Inflammation and Disruption of Blood-Brain Barrier.

Journal: Cells

Published: April 18, 2024

Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.

Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.

Journal: Biochemical pharmacology

Published: April 16, 2024

Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue.

Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue.

Journal: Biochemical pharmacology

Published: January 14, 2024

The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.

The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 04, 2022

Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.

Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.

Journal: Journal of personalized medicine

Published: June 07, 2022

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Journal: International journal of molecular sciences

Published: April 29, 2022

Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers.

Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers.

Journal: Scientific reports

Published: March 02, 2022

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

Journal: Frontiers in pharmacology

Published: December 09, 2021

Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy.

Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy.

Journal: Cells

Published: November 16, 2021

Adipokines and Inflammation: Focus on Cardiovascular Diseases.

Adipokines and Inflammation: Focus on Cardiovascular Diseases.

Journal: International journal of molecular sciences

Published: September 15, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026